Already a DIA Member? Sign in. Not a member? Join.
Sign in
Not a Member?
Pathway to Patient Access for CAR-T Therapies in Canada
Published Date: Oct 01, 2020This article overviews the introduction of CAR-Ts into the Canadian environment and adjustments in HTA processes and closely managed access to these products that may provide lessons for future highly specialized therapies.
Author(s)
Judith L. Glennie
President
J.L. Glennie Consulting Inc.
Dr. Judith Glennie is President of J.L. Glennie Consulting Inc., and a senior member of the healthcare community with more than 25 years of experience in national and international pharmaceutical policy. A clinical pharmacist by background, she has held roles in strategy, policy, teaching, research, and patient care in the payer, regulator, industry, clinical, and academic environments. Judy has led HTA policy initiatives as well as post-marketing effectiveness research, strategic planning, reimbursement submissions, and market access strategies for Janssen Canada; and served as both Manager and Director at Health Canada's Health Products and Foods Branch; and in a Federal Cabinet appointment to the Patented Medicine Prices Review Board.